Effects of solanezumab versus placebo administration on biomarkers in people with mild-to-moderate Alzheimer's disease: Results from two phase III clinical trials
2013
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI